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Abstract
Background: The mechanisms underlying tolerance induction and maintenance in autoimmune arthritis remain
elusive. In a mouse model of rheumatoid arthritis, collagen type II (CII)-induced arthritis, we explore the contribution of
B cells to antigen-specific tolerance.
Methods: To generate expression of the CII-peptide specifically on B-cell major histocompatibility complex type II,
lentiviral-based gene therapy including a B-cell-specific Igk promoter was used.
Results: Presentation of the CII-peptide on B cells significantly reduced the frequency and severity of arthritis as well as
the serum levels of CII -specific IgG antibodies. Further, both frequency and suppressive function of regulatory T cells
were increased in tolerized mice. Adoptive transfer of regulatory T cells from tolerized mice to naïve mice ameliorated
the development of CII-induced arthritis.
Conclusion: Our data suggest that endogenous presentation of the CII-peptide on B cells is one of the key
contributors to arthritis tolerance induction and maintenance.
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Background
The pathogenesis of rheumatoid arthritis (RA) is com-
plex and not fully understood. A hallmark of RA is the
production of autoantibodies to citrullinated proteins
and to IgG (rheumatoid factor). These are present in
serum and produced in the joints [1–3]. Antibodies are
produced by B cells, and during the last decade this cell
type has regained interest as a pathogenic cell because
autoantibody production precedes the onset of RA [4].
Moreover, therapies that target B cells by either deple-
tion or decreased survival (rituximab, anti-BAFF) have
been introduced as successful treatment strategies [5]. B
cells do not only play a role as (auto)antibody-producing
cells, however, because in experimental models these
cells have also been suggested to have a regulatory func-
tion, associated with their production of, for example,
IL-10 and IL-35 [6–8]. Further, B cells have the capacity
to induce regulatory T cells (Tregs) [9] and B-cell spe-
cific genes are up-regulated in transplantation tolerance
[10]. Harnessing the regulatory role of B cells could thus
potentially be used to re-establish tolerance.
The most commonly used mouse model of RA is col-
lagen-induced arthritis (CIA). This model is dependent on
the presentation of a defined collagen type II (CII) peptide
(amino acids 259–270) on the major histocompatibility
complex type II (MHC II) allele Aq on antigen-presenting
cells (APCs) and subsequent activation of antigen-specific
T cells and B cells [11]. The B-cell response is crucial for
development of CIA, as B-cell-deficient mice are resistant
to CIA [12] and B-cell depletion before immunization de-
lays development of CIA [13].
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Oral feeding with CII prior to induction of CIA has
been shown to ameliorate arthritis development [14],
but it may also enhance the disease [15]. A more pro-
nounced and specific suppression of arthritis and hence
CII immune tolerance has been achieved by intravenous
injection of a fusion protein consisting of MHC II and
glycosylated CII-peptide amino acids 259–270 [16].
However, it is still not known whether B cells are suitable
for tolerance induction in CIA. This study aims to investi-
gate whether expression of the CII-peptide, loaded onto
Aq on B cells, induces CII tolerance and regulates CIA.
We have shown previously that administration of
lentiviral particles which results in expression of the
CII-peptide on all APCs induces tolerance [17–19].
Here, we use our lentiviral system to target expression
of the CII-peptide specifically on B cells, using a B-cell
specific Igk promoter [20]. We show that endogenous
presentation of the CII-peptide on B cells initiates and
sustains tolerance to CIA. The results suggest that antigen
presentation by B cells is sufficient to confer tolerance in
CIA, and the model provides new insights into tolerance
mechanisms.
Methods
Lentiviral vectors
Generation of the CII-expressing lentiviral vector (LNT-
SFFV-CII/Ctrl; Additional file 1: Figure S1) has been de-
scribed previously [17]. Briefly, CII amino acids 259–270
was cloned into the class II-associated invariant chain
peptide position (CLIP) position of the invariant chain
(Ii) to achieve efficient loading of and binding to MHC
II. As a control vector, the original CLIP sequence was
kept in Ii. To generate a specific expression of the CII-
peptide on B-cell Aq, the Ii fragments were subcloned
into the lentiviral vector pHR′SIN-cPPT-SFFV with an
Igk promoter for B-cell specific expression [20] and were
named LNT-Igk-CII and LNT-Igk-Ctrl (Fig. 1a). The
linker AGCTTCAATTGTACGTACTCGAGCCGC was
added to plasmid Igk-E-eGFP between the HindIII and
SacII sites, cleaved with MfeI and XhoI, and ligated to
the Ii-CII and Ii-CLIP fragments isolated from pIi-CII
and pIi-CLIP following digestion with EcoRI and XhoI.
The lentiviral vector pTZ18R was ligated to linker AGCT
CAATTGGTACCTACGTACTCGAGACTAGT between
HindIII and EcoRI. Subsequently, the Igk promoter and
the plasmids containing Ii-CII and Ii-CLIP were digested
with KpnI and XhoI and were ligated into the KpnI and
XhoI sites in the linker in pTZ18R, resulting in LNT-Igk-
CII and LNT-Igk-Ctrl.
Sequencing was performed on the Ion Torrent plat-
form (Thermo Fisher Scientific, Carlsbad, CA, USA) to
confirm the plasmid sequence. Purified plasmid (1 μg)
was sheared and size selected to 200 base pairs (bp)
using the Ion Xpress Plus Fragment Library Kit in a
Library Builder instrument (Thermo Fisher Scientific). A
suitable dilution of the template was calculated after
quantification using the Ion Library quantitation kit
(Thermo Fisher Scientific). The diluted library was
loaded on an Ion One Touch 2 instrument (Thermo
Fisher Scientific) using the 200 bp chemistry kit to per-
form emulation PCR on Ion Sphere particles, which
were loaded on an Ion 314 chip v2. Sequencing was then
performed with the Hi-Q Sequencing Kit on an Ion per-
sonal genome machine (PGM; Thermo Fisher Scientific)
Fig. 1 Lentiviral vector design, integration and expression of the CII-peptide on MHC II. a Lentiviral vectors with an Igk promoter and the
collagen type II (CII) amino acids 259–270 peptide cloned into the Ii (LNT-Igk-CII) and the control vector with the original class II-associated
invariant chain peptide (CLIP) sequence (LNT-Igk-Ctrl). LTR long terminal repeat, WPRE woodchuck post-transcriptional regulatory element, cPPT
central polypurine tract. b Confirmation of vector integration, detected as WPRE DNA fragment, in cells from spleen and lymph from recipient
mice 22 weeks after intravenous injection of transduced CD34+ cells. c Proliferation index of 5 × 105 T-cell hybridomas specific for hydroxylated
(Hdbr1), glycosylated (Hcq3) and naked (Hcq4) CII-peptide co-cultured with 5 × 106 Igk-CII cells from spleen and peritoneal lavage
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using default parameters in Ion Torrent Suite version 4.6.
The obtained fastaq sequence files were imported into the
CLC Genomics Workbench software (QIAGEN Aarhus,
Denmark) to create a consensus sequence after mapping
to a reference sequence representing the vector construct
as well as by de-novo analysis (Additional file 2: Figure
S2): LNT-Igk-CII [GenBank:KU879253] and LNT-Igk-Ctrl
[GenBank:KU879254].
Production of lentiviral particles
Vesicular stomatitis virus G pseudotyped lentivirus was
produced by transient transfection of 293T cells with
three plasmids—the self-inactivating transfer vector
plasmid LNT-Igk-CII, LNT-Igk-Ctrl, LNT-SFFV-CII or
LNT-SFFV-Ctrl, the multi-deleted packaging plasmid;
pCMVΔR8.74 and the VSV-G envelope; or pMD.G2—and
titrated as described previously [18].
Mice
Male DBA/1 mice, 6–8 weeks old, were obtained from
Taconic (Europe A/S, Ry, Denmark) and housed in a
pathogen-free barrier facility (12-h light/12-h dark cycle)
and fed rodent chow. The local Animal Ethics Committee
approved all animal studies (numbers, 105-2009 and 277-
2011).
Transplantation of haematopoietic stem cells
Both donor and recipient mice were treated with Baytril®
(0.6 mg/ml) in the drinking water before transplantation,
and the treatment continued for the recipients 2 weeks
after transplantation. Bone marrow cells were harvested
from the femur and os ilium of DBA/1 mice and
haematopoietic stem cells (HSCs) were purified using
the EasySep™ Mouse Hematopoietic Progenitor Cell
Enrichment Kit (Stemcell Technologies, Manchester, UK).
Purified HSCs were cultured overnight under standard
conditions in StemSpan expansion medium (Stemcell
Technologies) with 100 ng/ml mSCF, 100 ng/ml mFlt3L,
100 ng/ml IL-11, 20 ng/ml IL-3 (R&D Systems, Abingdon,
UK) and lentiviral particles at multiplicity of infection
75 (LNT-SFFV-CII/Ctrl) or 40 (LNT-Igk-CII/Ctrl).
The following day, cells were re-suspended and
washed before intravenous injection of 2.5 × 105 cells
into syngeneic lethally irradiated (8.5 Gray) recipient
naïve mice. The cells were allowed to repopulate the
mice for a minimum of 10 weeks before induction of
CIA or adoptive transfer into naïve syngeneic recipi-
ent mice. The arthritis experiments using the Igk pro-
moter system were repeated independently three times
with a total of n = 26 LNT-Igk-Ctrl mice and n = 25 LNT
Igk-CII mice and terminated at various time points. Adop-
tive transfer of Tregs from LNT-Igk-CII/Ctrl mice and B
cells from mice transplanted with LNT-SFFV-CII/Ctrl was
performed once.
Confirmation of vector integration and Ii-CII expression
To confirm the presence of vector integration in spleen
and lymph node cells 22 weeks after bone marrow trans-
plantation, DNA was extracted from lymph nodes using
the Allprep DNA/RNA mini prep kit and from splenocytes
using the QIAamp DNA minikit (Qiagen). WPRE se-
quences were amplified by Taqman Universal PCR (Applied
Biosystems, Carlsbad, CA, USA) and normalized to the
amplification of the titin gene, as described previously [21].
Detection of CII protein expression on MHC II
To investigate presentation of the CII-peptide on MHC
II molecules, T-cell hybridomas specific for modified CII-
peptides were used: Hcq3 hybridoma (recognizes glycosyl-
ated CII amino acids 259–270), Hcq4 (recognizes naked
CII amino acids 259–270) and HdBr1 (recognizes hydrox-
ylated CII amino acids 259–270). To ensure proper speci-
ficity of the hybridoma, 5 × 104 cells from each hybridoma
were co-cultured in a 96-well plate for 24 hours with 5 ×
105 splenocytes that were primed with 20, 10, 5, 2.5 μg/ml
naked CII-peptide, 20, 5, 1.25, 0.4 μg/ml hydroxylated
CII-peptide or 20, 5, 1.25, 0.4 μg/ml glycosylated
CII-peptide. Analysis of IL-2 levels in supernatants was
performed using ELISA (R&D Systems) and showed spe-
cific peptide responses for each hybridoma (Additional file
1: Figure S1). The specific T-cell hybridomas were then
used to investigate CII-peptide expression on Aq on cells
from the peritoneal cavity and spleen 12 weeks after
transplantation. Peritoneal cavities were flushed with
PBS to harvest peritoneal cells and the spleen was re-
moved from transplanted mice (n = 3 per group). The
spleens were squeezed through a 70 μm cell strainer.
After spinning and washing, the cells were counted
(Nucleocounter; ChemoMetec A/S, Allerød, Denmark)
and seeded at 2.5 × 106 cells/ml on a 96-well plate in du-
plicate and co-cultured with T-cell hybridomas at 2.5 ×
105 cells/ml for 24 h. The levels of IL-2 in culture super-
natants were measured by ELISA.
Collagen-induced arthritis
The mice were immunized in the tail base with rat CII
(1 mg/ml) and complete Freund’s adjuvant (CFA; Sigma-
Aldrich, Stockholm, Sweden) in a total volume of 100 μl
and boosted 21 or 28 days later with CII (1 mg/ml,
100 μg/mouse) in incomplete Freund’s adjuvant (Sigma-
Aldrich). The intervals between the primary immunization
and booster vary due to a change in the ethical permit.
Arthritis severity and frequency were graded blindly at the
indicated time points after CII immunization. All of the
mice were followed up individually and arthritis (defined
as visible erythema and/or joint swelling) was evaluated by
inspection of finger/toe and ankle/wrist joints. Severity of
arthritis was evaluated by macroscopic inspection of each
limb, and a score was assigned for each limb: 0, neither
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swelling nor erythema; 1, mild swelling and/or erythema;
2, moderate swelling and erythema; and 3, marked swell-
ing and erythema. The total score for each mouse was cal-
culated by adding up the scores for each limb.
Histological examination of inflamed joints
Histopathologic examination of the joints was performed
after routine fixation, decalcification and paraffin embed-
ding. Tissue sections from fore and hind paws were cut and
stained with haematoxylin and eosin. All the slides were
coded and evaluated by two blinded observers. The speci-
mens were evaluated with regard to synovial hypertrophy,
leukocyte infiltration and cartilage/bone destruction. The
degree of synovitis and destruction in every joint region
(finger/toes, wrists/ankles, elbows and knees) was assigned
a score from 0 to 3. Occasionally, one paw was missing in
the histological sections, or embedded in such a way that
it was impossible to evaluate the degree of synovitis and
bone/cartilage destruction. Therefore, the total score per
mouse was divided by the number of joints evaluated.
Flow cytometry
Single cell suspensions were prepared from the spleen
and blood. Spleens were filtrated through cell strainers
before washing and centrifugation for 10 min at
1500 rpm. The blood was collected in Eppendorf tubes
containing heparin. Erythrocytes were lysed using lysis
buffer (0.16 M NH4Cl, 0.13 mM EDTA, 12 mM
NaHCO3). Cells were resuspended in PBS with 10 %
FCS, counted in a Nucleocounter and seeded in 96-
well plates. Fcγ receptors were blocked (clone 2.4G2;
BD Biosciences, Franklin Lakes, New Jersey, USA) be-
fore application of surface antibodies. T cells were
stained using CD4 (V450 clone RM4-5; BD Biosci-
ences) and CD25 (FITC, clone 3C7; BD Biosciences)
for 20 min at room temperature (RT). Intracellular stain-
ing was performed using FoxP3/Transcription Factor
Staining Buffer set (eBioscience, San Diego, USA) and
FoxP3 (phycoerythrin (PE), clone NRRF-30; eBioscience,
San Diego, USA) or an isotype control (PE, clone eBR2a)
for 30 min at 8 °C. Cells were detected by FACSCanto II™
(BD Biosciences) and analysis was performed by FlowJo
Software (Tree Star Inc., Ashland, OR, USA). Gates for
both surface and intracellular staining were set according
to flourochrome minus one settings [22].
CII-specific IgG and IgM antibodies and total IgG
antibodies in serum
Levels of CII-specific IgG in serum, collected at indicated
time points after CII immunization, were determined by
ELISA. Low binding plates (NUNC, Fisher Scientific,
Gothenburg, Sweden) were coated with rat CII (1 μg/ml)
in PBS. Serum samples were diluted (1/7500, 1/22,500,
1/67,500 and 1/202,500) and after incubation CII-specific
IgG was detected by biotinylated rat anti-mouse IgG,
IgG1, IgG2a or IgG2b at 0.5 μg/ml (Serotec, Oxford, UK)
or biotinylated (Fab)2 goat anti-mouse IgM (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA).
The assays were developed using extravidin–horseradish
peroxidase (HRP) and tetramethylbenzidine substrate.
The reactions were stopped with H2SO4 and read in Spec-
tra Max 340PC (Molecular Devices, Sunnyvale, CA, USA)
at 450 nm with correction at 650 nm.
Anti-recombinant CII epitope ELISA assay
A 96-well plate was coated with anti-recombinant CII-
peptides at 5 μg/ml, 100 μl/well and incubated at 4 °C
overnight. The plate was blocked with 0.3 % milk pow-
der for 2 h at RT. Serum diluted 1:100 was added to the
plate and incubated for 2 h at RT. Rat Anti-Mouse
Kappa-HRP (clone 187.1; Southern Biotech, Bromma,
Sweden) was added at dilution 1:4000. The assay was de-
veloped using ABTS substrate and buffer (Roche Life
Science, Bromma, Sweden) and read at 405 nm.
Mycobacterium tuberculosis IgG ELISA
Heat-killed Mycobacterium tuberculosis H37Ra (Difco, BD
Biosciences, Franklin Lakes, New Jersey, USA) 0.4 mg/ml
was dissolved in carbonate buffer, and filtered through a
22 μm Millipore filter. A 96-well plate (Nunc Maxisorp)
was coated with 100 μl per well of the M. tuberculosis
solution and incubated at 4 °C overnight and further
blocked with PBS with BSA 1 %, Tween 1 %. The serum
was serially diluted from 1:8 to 1:512 and the plate was in-
cubated at 4 °C overnight. Biotinylated goat anti-mouse
IgG (Jackson) was added at dilution 1:3000. The assays
were developed using streptavidin–HRP (R&D) and tetra-
methylbenzidine substrate. The plate was read at 450 nm.
Immunofluorescent staining of tissue sections
Mouse spleen tissue embedded in OCT (Histolab, Västra
Frölunda, Sweden) was snap-frozen using dry ice. Frozen
tissue was cut in 7 μm thick sections on a Leica CM3050
cryostat. Tissue slides were fixated in ice-cold ethanol for
10 min and allowed to air dry, then either stained immedi-
ately or kept at –20 °C until staining. Slides were put in
PBS for 5 min to remove OCT and then mounted into a
Shandon cover plate Sequenza slide rack (Thermo Fisher
Scientific, Västra Frölunda, Sweden). Unspecific binding
was blocked using diluted horse serum or DAKO protein
block. Antibodies for detection of surface markers rat
anti-mouse B220 (biotinylated, RA3-6B2; BD Pharmingen,
Franklin Lakes, New Jersey, USA), hamster anti-mouse
TCRβ (Alexa Fluor 488, H57-597; Biolegend, San Diego,
CA, USA) and rat anti-mouse GL7 (e660 GL-7;
eBioscience, San Diego, USA) were diluted in PBS and ap-
plied to sections, and incubated overnight at 4 °C. For
intracellular staining of Foxp3, sections were incubated
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with 4 % PFA in PBS for 5 min, then 0.5 % Triton-X-100
for 5 min, blocked with protein block (DAKO, Stockholm,
Sweden) and then stained with rat anti-mouse foxp3
(e570, FKJ-16 s; eBioscience, San Diego, USA) diluted in
0.1 % saponin in PBS. Slides were washed three times with
PBS–saponin and mounted with fluorescent mounting
medium (DAKO, Stockholm, Sweden). Images were ac-
quired on a Zeiss LSM 700 confocal image fluorescent
microscope with ZEN 2009 acquisition software
(Zeiss, Oberkochen, Germany) at 1.6 pixels per μm. The
number of GL7 clusters were counted and divided by
the number of follicles per slide. A mean of duplicate
slides was calculated per individual mouse.
T-cell suppression assay
Single cell suspensions were prepared from the spleen
and lymph nodes of LNT-Igk-CII/Ctrl mice (n = 3 per
group). Erythrocytes were depleted from single cell
suspensions using anti-TER 119 micro beads (Miltenyi
Biotech). Cell suspension was then stained for surface ex-
pression of anti-CD4 (allophycocyanin (APC), RM4-5; BD
Biosciences) and anti-CD25 (PE, PC61; BD Biosciences)
and sorted into a CD4+CD25+ Treg population using a
FACS Sy3200 Sorter (Sony Biotechnology, Champaign, IL,
USA). Tregs were expanded for 8 days using a Treg Ex-
pansion Kit (Miltenyi Biotech Norden AB, Lund, Sweden).
MHC II+ APCs and CD4+CD25– effector T cells were
sorted from the spleen of naïve DBA/1 mice. Before sort-
ing, erythrocytes were depleted from single cell suspen-
sions using anti-TER 119 micro beads (Miltenyi Biotech)
and stained with anti-CD4 (APC, RM4-5; BD Biosciences),
anti-CD25 (PE, PC61; BD Biosciences) and anti-MHC II
(APC-e780; eBioscience, San Diego, USA). Sorted Tregs
were stained with 10 μM CellTrace violet at 37 °C. APCs
(5 × 104), effector T cells (2 × 104) and Tregs (according to
ratio) were seeded in DMEM (supplemented with 10 %
FCS, 1 % 2-mercaptoethanol, 1 % penicillin/streptomycin)
with added anti-CD3 (azide free; BD Biosciences) at a final
concentration of 0.5 μg/ml in a 96-well plate. After 6 days,
proliferation was evaluated by CellTrace violet fluores-
cence of cells acquired on a FACSCanto II™.
Adoptive transfers
Adoptive transfer of CD4+CD25+ T cells from LNT-Igk-
Ctrl/CII mice to naïve recipients was carried out before
CII immunization. Eighteen weeks after transplantation,
CD4+CD25+ cells were sorted from spleen and lymph
node cells of LNT-Igk-CII/Ctrl mice (n = 4 per group)
using a FACS Sy3200 Sorter (Sony Biotechnology).
Erythrocytes were depleted from single cell suspensions
using anti-TER 119 micro beads (Miltenyi Biotech) and
the remaining cells were stained with anti-CD4 (APC,
RM4-5; BD Biosciences) and anti-CD25 (PE, PC61; BD
Biosciences). Following 30 min of incubation at 4 °C,
cells were washed and sorted by FACS (Additional file 3:
Figure S3A). Purity and viability of isolated cells was
around 90–95 % (Additional file 3: Figure S3B). Tregs
were expanded for 8 days using a Treg Expansion Kit
(Miltenyi Biotech). CD4+CD25+ T cells (5.5 × 105 per
mouse) were adoptively transferred into naïve syngeneic
recipient mice 2 days before CII immunization and arth-
ritis development was evaluated as already described.
CD19+MHC II+ B cells from LNT-SFFV-CII/Ctrl mice
were transferred to naïve DBA/1 mice 28 days after CII
immunization. Fourteen weeks after transplantation of
LNT-SFFV-CII/Ctrl transduced HSCs, B cells (defined as
both CD19+ and MHC II+ cells) were sorted by FACS Syn-
ergy (Additional file 3: Figure S3C). Briefly, single cell sus-
pensions were prepared in PBS with 10 % FCS. APC-Cy7
Rat Anti-Mouse CD19 (BD Pharmingen) and eFlour450
Anti-mouse MHC class II (I-A/I-E) (eBioscience, San
Diego, USA) were added to the cell suspensions and, fol-
lowing a 30-min incubation at 4 °C, cells were washed and
then sorted by FACS. The freshly isolated B cells (2 × 106)
were adoptively transferred into syngeneic recipient mice
28 days after CII immunization and evaluated for develop-
ment of arthritis as already described.
Statistical analysis
Statistical analyses were performed using GraphPad
Prism (La Jolla, CA, USA). Statistical differences be-
tween parametrically distributed groups were calculated
using Student’s t test, with a Bonferroni correction for
multiple comparisons when applicable, and for two-
variable datasets a two-way ANOVA was used. Differ-
ences between non-parametrically distributed groups
were calculated using the Mann–Whitney U test for
quantitative data and Fisher’s exact test for nominal data.
Linear regression was used to compare development of
severity of arthritis between treatment groups. P < 0.05
was considered significant.
Results
B cells express the CII-peptide in its naked non-modified
form
Presentation of the immunodominant T-cell epitope in
CII, the CII-peptide amino acids 259–270, on MHC II Aq
is important for both disease development [23, 24] and
tolerance [16, 17, 25]. We have shown previously that
adoptive transfer of B cells presenting the CII - peptide on
MHC II Aq induces partial tolerance to CIA [19]. In these
experiments we used the LNT-SFFV-CII/CLIP lentiviral
vectors, where expression of CII was driven by the general
SFFV promoter (Additional file 3: Figure S3B). To test the
hypothesis that B cells are important mediators of
antigen-specific tolerance, we generated a lentiviral vector
where the expression of the CII-peptide was driven by the
B-cell specific k light chain (Igk) promoter [20] (LNT-Igk-
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CII) and a control vector containing the native CLIP pep-
tide (LNT-Igk-Ctrl) (Fig. 1a). The expected efficacy of the
Igk promoter is transgene expression in around 10 % of B
cells [20]. To express the CII-peptide on MHC II Aq, we
transduced HSCs with the selected lentiviral particles and
subsequently injected the HSCs into lethally irradiated re-
cipient mice. The mice were allowed to reconstitute their
haematopoietic cell populations for at least 10 weeks be-
fore cells were harvested or CIA was induced.
Vector integration was confirmed by quantitative PCR
analysis of the woodchuck post-transcriptional regula-
tory element (WPRE) DNA sequence in cells from the
spleen and lymph node from LNT-Igk-CII and LNT-
Igk-Ctrl after HSC reconstitution (Fig. 1b). Protein
expression of the CII-peptide on B-cell Aq was veri-
fied using CII-specific T-cell hybridomas recognizing
post-translational modified forms of the CII-peptide [26].
We found that all hybridomas were functional and
responded to the expected peptide (Additional file 1:
Figure S1A) and that the CII-peptide, predominantly the
naked non-modified variant, was weakly expressed on
cells from both spleen and peritoneal lavage (Fig. 1c).
Frequency and severity of arthritis is reduced in
LNT-Igk-CII mice
Clinical evaluation of arthritis showed a delayed onset
and reduced frequency of arthritis in LNT-Igk-CII mice
(53 %) compared with LNT-Igk-Ctrl mice (95 %)
(Fig. 2a). The severity of arthritis was also greatly re-
duced in LNT-Igk-CII mice compared with LNT-Igk-
Ctrl mice and remained at this low level throughout the
course of arthritis (Fig. 2b). The histological scores
showed a considerably milder pathology in LNT-Igk-CII
mice with reduced synovitis and erosion score compared
with LNT-Igk-Ctrl mice (Fig. 2c), hence confirming
the clinical evaluation of arthritis. However, when
CII-expressing B cells from non-immunized transplanted
mice were transferred to mice after CII immunization, no
effect on arthritis development was detected (Additional
file 1: Figure S1C).
LNT-Igk-CII mice display reduced levels and a limited
repertoire of CII-specific IgG antibodies
As development of CIA is dependent on CII-specific anti-
bodies [27, 28], serum levels of CII-specific antibodies were
determined at the indicated time points. CII-specific IgG
antibodies were detected in all animals after immunization,
but the levels were significantly decreased in LNT-Igk-CII
mice compared with LNT-Igk-Ctrl mice with the highest
level 40 days after immunization (Fig. 3a). At this time
point, the levels of CII-specific IgG1 and IgG2a were
reduced in LNT-Igk-CII mice (Fig. 3b–d). However, there
were no differences in serum levels of CII-specific IgM anti-
bodies between the LNT-Igk-CII or LNT-Igk-Ctrl mice at
days 0 or at days 7, 15 and 29 days after immunization
(Fig. 3e). CII expression on B cells thus impaired the IgG
but not IgM response to CII, indicating that the tolerogenic
effect of the B cells involved T cells.
In CIA, the CII-specific IgG response is heterogeneous
and results in antibodies to several well-defined CII epi-
topes. Antibodies directed to epitopes such as C1, J1, D3
and U1 mediate disease [29] while others such as those
to F4 are considered protective [30]. We hypothesized
that there would be a shift in the antigen specificity be-
tween LNT-Igk-Ctrl versus LNT-Igk-CII mice. We de-
termined the delta change in serum levels of CII-specific
Fig. 2 CIA development in LNT-Igk-Ctrl and LNT-Igk-CII mice. a Arthritis frequency and b clinical severity after CIA induction in LNT-Igk-Ctrl and
LNT-Igk-CII mice. c Histopathological evaluation of synovitis and joint erosions at day 40 after CIA induction (n = 10 per group, one of three
experiments is shown). Indicated P values were determined using Fisher’s exact test for nominal data, linear regression to compare the severity of
arthritis (shown as mean ± SD) and a non-parametric test for categorical data. *P < 0.05; **P < 0.01; ***P < 0.001
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IgG antibodies targeting these epitopes, from baseline
and after immunization. In LNT-Igk-Ctrl mice, IgG anti-
bodies to all CII epitopes except F4 were increased from
baseline (day 0). By contrast, the LNT-Igk-CII mice did
not mount an IgG response except to the C1 epitope,
which was delayed and lower demonstrating that the
CII-specific IgG response to disease-mediating epitopes
is substantially reduced (Fig. 3f ).
Reduced germinal centre formation in LNT-Igk-CII mice
The reduction in the CII-specific IgG response in LNT-
Igk-CII mice suggested a T-cell-mediated effect, which
Fig. 3 Anti-CII IgG and IgM in serum from LNT-Igk-Ctrl and LNT-Igk-CII mice. Serum levels of a anti-CII IgG, b anti-CII IgG1, c anti-CII IgG2a, d anti-CII
IgG2b and e anti-CII IgM in LNT-Igk-Ctrl and LNT-Igk-CII mice measured by ELISA at day 20, day 40 (n = 10 per group) and day 55 (n = 6 per group) after
immunization. f Change in serum levels of the IgG antibodies to the specific CII epitopes (C1, J1, D3, U1, E10 and F4) measured as Δabsorbance
(absorbance at indicated day – mean value at day 0). Serum was obtained from LNT-Igk-Ctrl and LNT-Igk-CII mice at day 0 (n = 3 per group), day 15
(n = 6 per group), day 40 (n = 10 per group) and day 55 (n = 7 and 6, respectively). Data shown as mean ± SEM. Indicated P values were determined
using a two-tailed t test with a Bonferroni correction for multiple comparisons when comparisons were made for multiple anti-recombinant CII-peptide
assays. *P < 0.05; **P < 0.01; ***P < 0.001
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could result in impaired germinal centre (GC) forma-
tion. The frequency of splenic GCs was determined at
day 15 after immunization and found to be similar in
both LNT-Igk-and LNT-Igk-Ctrl mice (Fig. 4a). As both
groups of mice mounted an IgG response to M. tubercu-
losis, which is a part of Freund’s complete adjuvant, the
GC formation in spleen after the primary immunization
(Additional file 1: Figure S1D) at day 15 does not have
to be CII specific. However, at day 29 (i.e. the day after
CII booster (in incomplete adjuvant)) only one mouse
out of three in the LNT-Igk-CII group displayed GC for-
mation, at the same time as the corresponding numbers
in the control group were three out of three mice
(Fig. 4b). These results indicate that B-cell specific ex-
pression of the CII-peptide in LNT-Igk-CII mice might
have an effect on the T-cell-dependent immune response
to CII.
Frequency and suppressive function of Tregs are
enhanced in LNT-Igk-CII mice
We have shown previously that tolerance induced by pres-
entation of the CII-peptide on Aq, driven by a general pro-
moter, is associated with an increased proportion of Tregs
[18, 19], which is consistent with Tregs as key mediators
of peripheral tolerance and their ability to prevent the de-
velopment of CIA [31]. We therefore hypothesized that
presentation of the CII-peptide on B cells in LNT-Igk-CII
mice had an effect on Tregs. Determining the frequency
of CD4+Foxp3+ Tregs in blood showed that it was similar
in LNT-Igk-Ctrl and LNT-Igk-CII mice before
immunization but increased significantly in LNT-Igk-CII
mice after immunization, at day 7 in blood (Fig. 5a) and
the same trend was seen at day 15 in spleen (Fig. 5b).
Moreover, the CD4+CD25+ Tregs from LNT-Igk-CII mice
were also functionally more potent, as they suppressed
proliferation of CD4+CD25– effector T cells more than did
CD4+CD25+ Tregs from LNT-Igk-Ctrl mice (Fig. 5c).
Tolerogenic effect in LNT-Igk-CII mice is partly mediated
by T cells
To confirm the antigen specificity of the Tregs in LNT-
Igk-CII mice, CD4+CD25+ was adoptively transferred to
naïve DBA/1 recipients 2 days before induction of arth-
ritis. The severity of arthritis was reduced in mice that
received CD4+CD25+ from LNT-Igk-CII mice compared
with those that received CD4+CD25+ Tregs from LNT-
Igk-Ctrl mice (Fig. 5d).
Discussion
In this study we demonstrate that expression of the CII-
peptide on B cells in the context of MHC II Aq is suffi-
cient to induce tolerance in the CIA model. Our results
suggest that the presentation of the CII-peptide on B
cells increases the frequency and suppressive capacity of
Tregs, and leads to decreased levels of CII-specific IgG
Fig. 4 Frequency of GCs in spleens from LNT-Igk-Ctrl and LNT-Igk-CII mice after CIA induction. Frequency of GCs per follicle in spleens a 15 days
after immunization from LNT-Igk-Ctrl mice (n = 6) and LNT-Igk-CII mice (n = 6) or b 29 days after immunization from LNT-Igk-Ctrl mice (n = 3) and
LNT-Igk-CII mice (n = 3). GC germinal centre
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antibodies and reduced frequency and severity of
arthritis.
Our results are supported by previous work implicat-
ing B cells in tolerance induction. Antigen presentation
by B cells prevents cognate activation of naive, but not
memory, T cells [32] and induces tolerance to soluble
antigen [33]. B cells can also induce and maintain toler-
ance by production of anti-inflammatory cytokines such
as IL-10, and B cells genetically or otherwise manipulated
to produce IL-10 have immunoregulatory properties in
autoimmune diseases [6, 7, 21, 34]. Gene therapy reintro-
ducing Wiskott–Aldrich protein in B cells prevented
Fig. 5 Frequency and suppressive capacity of Tregs. Treg frequency in a blood and b the spleen from LNT-Igk-Ctrl and LNT-Igk-CII mice at
indicated time points during CIA. Indicated P values are calculated using Student’s t test. c Proliferation of Teffs (CD4+CD25–) from naïve DBA1
mice, stimulated for 6 days with APCs and αCD3 in the presence of Tregs (CD4+CD25+) from LNT-Igk-CII mice (n = 3) and LNT-Igk-Ctrl mice (n = 3)
in Tregs: Teff ratio 1:1 (flow cytometry plot), 1:5 and 1:10. Two-way ANOVA was used to calculate P values. d Clinical severity of arthritis in mice
that received Tregs from LNT-Igk-Ctrl mice (n = 5) or LNT-Igk-CII mice (n = 6) 2 days before CIA induction. The indicated P value is calculated using
a comparison between slopes after linear regression and data are shown as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001. CIA collagen-induced
arthritis, CII collagen type II, Teff effector T cell, Treg T regulatory cell
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development of autoreactive B-cell clones in Wiskott–Al-
drich syndrome patients [35], highlighting the importance
of B cells for tolerance.
Development of CIA is dependent on both T cells [36]
and B cells [37]. Further, germline-encoded IgM and IgG
CII-specific B cells are not eliminated by central toler-
ance mechanisms [38, 39]. During CIA T-cell help is
needed to enhance the polyclonal expansion, but also
the generation, of autoreactive IgG CII-specific B cells
[36]. CII-specific antibodies with specificity for different
CII epitopes seem to have different pathogenicity; anti-F4
IgG antibodies have been suggested to protect against
arthritis, while C1, J1, D3, U1 and E10 IgG antibodies me-
diate arthritis [30]. We show that after CII immunization,
LNT-Igk-Ctrl mice but not LNT-Igk-CII mice developed
CII-specific IgG antibodies reactive with all measured CII
epitopes. However, there was no increase in anti-F4 IgG in
LNT-Igk-CII mice after immunization, suggesting that the
tolerance observed is not mediated by production of pro-
tective antibodies. Rather, the pathogenic CII antibodies
that are evident in the control mice are lacking in the
LNT-Igk-CII mice.
The initial immunization using complete Freund’s ad-
juvant contains a number of soluble antigens besides CII
that trigger GC formation which leads to M. tuberculosis
specific IgG antibodies [40]. However, booster exposure
to the CII antigen reactivates the CII-specific memory T
cells and B cells and leads to rapid GC formation and in-
creased antibody diversity [41] seen in the control, but
not in the LNT-Igk-CII mice.
It has become clear that professional APCs, such as
dendritic cells but also B cells, are important for devel-
opment of the Foxp3+ Treg compartment by different
mechanisms including IL-10, IL-35 and TGF-β produc-
tion [42]. Intravenous administration of antigen without
adjuvant often leads to tolerance, where the B cells pas-
sively take up antigen and present on MHC II [43],
which in turn appears to promote Treg differentiation
[44]. In addition, passive uptake of CII may lead to a
weaker T-cell activation [45] than antigen-specific in-
ternalization. Regardless of whether our CII-presenting
B cells acquire a regulatory phenotype [46] or whether
they represent a naïve phenotype when presenting the
peptide [47], the results suggest that they promote
Treg development and/or T-cell inactivation rather
than T-cell activation [9, 44]. Furthermore, adoptive
transfer of Tregs from LNT-Igk-CII mice was super-
ior in transferring tolerance, compared with Tregs
from LNT-Igk-Ctrl mice. We could not detect an in-
creased frequency of an IL-10-producing regulatory B-
cell phenotype or transitional type 2 marginal zone
precursor cells (data not shown) in LNT-Igk-CII mice,
which would indicate an expansion of Bregs. This was
also supported by the fact that adoptive transfer of
CII-presenting B cells could not transfer tolerance to
already immunized mice.
Both T-follicular helper cells and Tregs are specific for
the immunizing antigen, but self-antigen preferentially
induces T-follicular regulatory cells over T-follicular
helper cells. T-follicular regulatory cells can derive from
peripheral Tregs [48]. In our experiments, the frequency
of Tregs was not increased before but well after CII
immunization, which was followed by decreased produc-
tion of CII-specific IgG antibodies and suppression of
arthritis in the Igk-CII mice. This observation could in-
dicate that the balance between T-follicular helper cells
and T-follicular regulatory cells are skewed towards the
latter. This might be of importance for the reduced CII-
specific IgG response observed in the LNT-IgK-CII
mice.
Conclusions
Taken together, these experiments suggest that the
tolerogenic effect of B cells in this model is mediated by
T-cell tolerance. The LNT-Igk-CII B cells will most
likely induce tolerance in heteroreactive T cells (i.e. T
cells recognizing the rat CII-peptide), which will prevent
the T-cell response to CII immunization and hence the
cross-reactivity leading to an autoreactive response.
Antigen presentation of the CII-peptide on B cells thus
induces and maintains tolerance, which in part is medi-
ated by Tregs.
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Additional file 1: is Figure S1 showing (A) verification of the functionality
of hybridomas shown as IL-2 production by T-cell hybridomas with TCR
specificity for hydroxylated (Hdbr1), glycosylated (Hcq3) or naked (Hcq4)
modifications of the lysine residue in the CII259-270 sequence. The different
hybridomas were co-cultured with splenocytes primed with naked,
hydroxylated or glycosylated CII - peptide at varying concentrations.
(B) Lentiviral vectors with an SFFV promoter and the CII amino acids
259–270 peptide cloned into Ii (LNT-SFFV-CII) or the control vector
with the original CLIP sequence (LNT-SFFV-Ctrl). LTR long terminal
repeat. (C) To determine whether B cells expressing CII-peptide could
mediate tolerance during ongoing arthritis, sorted B cells were adop-
tively transferred to recipient mice at day 28 after CII-immunization (mice
were boosted at day 21 in this experiment). As expression from the Igk pro-
moter is low [19] B cells from LNT-SFFV-CII (n = 7) or LNT-SFFV-Ctrl mice (n
= 7) were used to generate a higher frequency of CII-expressing B cells.
However, in the effector phase of arthritis, the sorted B cells could not
hamper development of arthritis. (D) M. tuberculosis IgG antibodies
correlate to the frequency of GCs at day 15, after the
primary immunization. (EPS 639 kb)
Additional file 2: is Figure S2 showing lentiviral vector maps.
(EPS 2084 kb)
Additional file 3: is Figure S3 showing FACS plots for adoptive transfer
of Tregs or B cells during, and after, sort. (EPS 2857 kb)
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